Adam Laponis Sells 2,597 Shares of Twist Bioscience (NASDAQ:TWST) Stock
by Teresa Graham · The Cerbat GemTwist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 2,597 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $49.89, for a total transaction of $129,564.33. Following the completion of the sale, the chief financial officer owned 125,694 shares in the company, valued at $6,270,873.66. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Adam Laponis also recently made the following trade(s):
- On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00.
- On Tuesday, January 13th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00.
Twist Bioscience Stock Performance
TWST stock traded up $2.47 during trading on Monday, reaching $50.38. 981,679 shares of the stock were exchanged, compared to its average volume of 1,282,704. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $57.88. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $3.09 billion, a P/E ratio of -39.36 and a beta of 2.20. The stock has a 50 day simple moving average of $47.78 and a 200-day simple moving average of $38.21.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. The firm’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the company. Evercore raised their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Guggenheim lifted their target price on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Finally, TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $46.50.
Read Our Latest Stock Report on Twist Bioscience
Institutional Trading of Twist Bioscience
A number of large investors have recently bought and sold shares of TWST. William Blair Investment Management LLC raised its stake in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares in the last quarter. EdgePoint Investment Group Inc. boosted its stake in shares of Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after purchasing an additional 1,696,377 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares during the last quarter. Millennium Management LLC increased its position in shares of Twist Bioscience by 151.5% during the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after purchasing an additional 1,080,722 shares in the last quarter. Finally, ARK Investment Management LLC increased its position in shares of Twist Bioscience by 12.4% during the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after purchasing an additional 832,687 shares in the last quarter.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.